...
首页> 外文期刊>Journal of affective disorders >Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study
【24h】

Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study

机译:双相门诊患者使用拉莫三嗪处方的临床因素:SIN-DEPRES研究的亚分析

获取原文
获取原文并翻译 | 示例

摘要

Background: The use of lamotrigine is a point of discrepancy among the diverse guidelines published on the management of bipolar disorder (BD). Evidence supporting the long-term efficacy is reasonably robust. Nonetheless, the effectiveness of lamotrigine in acute treatment is vigorously debated and it is unclear how this drug is used in routine clinical practice. This subanalysis of the SIN-DEPRES study was designed to understand the clinical profile of bipolar patients receiving lamotrigine. Methods: In this prospective national multicenter study, 652 patients with clinically stable bipolar I and II disorder were recruited. Clinical assessments included sociodemographic and clinical data, the Modified Clinical Global Impression scale for BD (CGI-BP-M), the Hamilton Depression Rating Scale (HDRS), and prescriptions of psychotropic medications and their doses. Results: By means of a logistic regression model, an association between receiving treatment with lamotrigine and the following clinical variables was found: number of past depressive episodes (O.R.=2.875, 95% CI: 1.203-6.869, p=0.018), depressive polarity of the most recent episode (O.R.=1.945, 95% CI: 1.267-2.985, p=0.002), severity in CGI-BD-M depression (O.R.=1.850, 95% CI: 1.215-2.817, p=0.004), bipolar II disorder diagnosis (O.R.=1.635, 95% CI: 1.078-2.482, p=0.021) and number of episodes per year (O.R.=1.310, 95% CI: 1.069-1.605, p=0.009). Limitations: Subanalysis of the SIN-DEPRES study with a cross-sectional design. Conclusions: The use of lamotrigine in clinical practice is in accordance with most of the guidelines, which support its use in patients with depressive predominant polarity and bipolar II disorder.
机译:背景:拉莫三嗪的使用是有关双相情感障碍(BD)管理的各种指南之间的一个差异点。支持长期疗效的证据相当可靠。然而,拉莫三嗪在急性治疗中的有效性受到了激烈的争论,目前尚不清楚该药物如何在常规临床实践中使用。 SIN-DEPRES研究的子分析旨在了解接受拉莫三嗪的双相型患者的临床特征。方法:在这项前瞻性国家多中心研究中,招募了652例临床稳定的I型和II型双相情感障碍患者。临床评估包括社会人口统计学和临床​​数据,改良的BD临床总体印象量表(CGI-BP-M),汉密尔顿抑郁量表(HDRS)以及精神药物处方及其剂量。结果:通过逻辑回归模型,发现接受拉莫三嗪治疗与以下临床变量之间的关联:过去抑郁发作的次数(OR = 2.875,95%CI:1.203-6.869,p = 0.018),抑郁极性最近发作的发生率(OR = 1.945,95%CI:1.267-2.985,p = 0.002),CGI-BD-M抑郁症的严重程度(OR = 1.850,95%CI:1.215-2.817,p = 0.004),双相II型疾病诊断(OR = 1.635,95%CI:1.078-2.482,p = 0.021)和每年发作次数(OR = 1.310,95%CI:1.069-1.605,p = 0.009)。局限性:SIN-DEPRES研究的子分析,采用横断面设计。结论:拉莫三嗪在临床实践中的使用符合大多数指南,这支持其在抑郁为主的极性和双相II型障碍患者中的​​使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号